1. Component Analysis
This protocol focuses on aggressive fat loss and muscle preservation. It uses the strongest clinically validated peptide for belly fat (Tesamorelin) and stacks it with standard growth hormone secretagogues.
- Tesamorelin (10mg):
- Role: The “Visceral Fat Specialist.” It is a potent Growth Hormone Releasing Hormone (GHRH) analog.
- Mechanism: It is the only peptide FDA-approved (under the brand name Egrifta) specifically to reduce visceral adipose tissue (belly fat surrounding organs) in HIV patients. It increases pulsatile GH release with a specific affinity for lipolysis (fat burning).
- CJC No DAC + Ipamorelin (Blend):
- Role: Sustained GH support and Muscle Preservation.
- Mechanism: As detailed in previous stacks, this combination stimulates the pituitary to release growth hormone. In this context, it is likely included to prevent “sarcopenia” (muscle wasting), which is a common side effect of rapid weight loss or GLP-1 agonist use.
- DSIP (Delta Sleep-Inducing Peptide):
- Role: Metabolic Recovery.
- Mechanism: Poor sleep drastically reduces insulin sensitivity and increases cortisol (which leads to belly fat). DSIP is included to ensure deep sleep, optimizing the metabolic environment for the other peptides to work.
2. Protocol Breakdown
Core Bundle
- Target: Patients with “stubborn” midsection fat, metabolic syndrome, or those on Semaglutide/Tirzepatide who want to avoid the “Ozempic Face” or muscle loss.
- The Logic: This is a “Burn and Build” stack.
- Tesamorelin is the primary engine for burning visceral fat.
- CJC/Ipamorelin acts as the anabolic safety net to keep muscle tissue intact while in a caloric deficit.
- DSIP manages the cortisol/stress component of weight loss.
